Clinical characteristics, univariate, and multivariate Cox model analysis of long-term (> 3 years) survivors of stage IV metastatic breast cancer treated on phase II or III North Central Cancer Treatment Group (NCCTG) trials.

Treatment Group ◽

Cancer Treatment ◽

Clinical Characteristics ◽

Cox Model ◽

Metastatic Breast ◽

Stage Iv ◽

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

Annals of Oncology ◽

10.1093/annonc/mdp328 ◽

2010 ◽

Vol 21 (3) ◽

pp. 493-497 ◽

Cited By ~ 9

Author(s):

W.W. Tan ◽

D.W. Hillman ◽

M. Salim ◽

D.W. Northfelt ◽

D.M. Anderson ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Metastatic Breast ◽

Phase 2 ◽

North Central ◽

Irinotecan Hydrochloride ◽

Phase 2 Trial

Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

Annals of Oncology ◽

10.1093/annonc/mdx811 ◽

2018 ◽

Vol 29 (10) ◽

pp. 2150

Author(s):

W.W. Tan ◽

D.W. Hillman ◽

M. Salim ◽

D.W. Northfelt ◽

D.M. Anderson ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Metastatic Breast ◽

Phase 2 ◽

North Central ◽

Irinotecan Hydrochloride ◽

Phase 2 Trial

Faculty of 1000 evaluation for N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718023021.793480259 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

North Central ◽

Previously Treated

North Central Cancer Treatment Group N0531: Phase II Trial of Weekly Albumin-Bound Paclitaxel (ABI-007; Abraxane®) in Combination with Gemcitabine in Patients with Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2005.n.042 ◽

2005 ◽

Vol 6 (4) ◽

pp. 361-364 ◽

Cited By ~ 13

Author(s):

Alvaro Moreno-Aspitia ◽

Edith A. Perez

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdp512 ◽

2010 ◽

Vol 21 (2) ◽

pp. 269-274 ◽

Cited By ~ 23

Author(s):

E.A. Perez ◽

D.W. Hillman ◽

T. Dentchev ◽

N.A. Le-Lindqwister ◽

L.H. Geeraerts ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

First Line ◽

North Central ◽

Line Chemotherapy

North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane

Clinical Breast Cancer ◽

10.1016/j.clbc.2012.09.007 ◽

2012 ◽

Vol 12 (6) ◽

pp. 387-391 ◽

Cited By ~ 13

Author(s):

Kostandinos Sideras ◽

Amylou C. Dueck ◽

Timothy J. Hobday ◽

Kendrith M. Rowland ◽

Jacob B. Allred ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

North Central ◽

Previously Treated ◽

Vegf Trap

Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer a collaborative north central cancer treatment group/mayo clinic phase ii study

Cancer ◽

10.1002/1097-0142(19900201)65:3<418::aid-cncr2820650307>3.0.co;2-k ◽

1990 ◽

Vol 65 (3) ◽

pp. 418-421 ◽

Cited By ~ 17

Author(s):

James E. Krook ◽

Charles L. Loprinzi ◽

Daniel J. Schaid ◽

Carl G. Kardinal ◽

James A. Mailliard ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Continuous Infusion ◽

Phase Ii ◽

Mayo Clinic ◽

Phase Ii Study ◽

Metastatic Breast ◽

N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial

Annals of Oncology ◽

10.1093/annonc/mdt213 ◽

2013 ◽

Vol 24 (10) ◽

pp. 2548-2554 ◽

Cited By ~ 7

Author(s):

W.W. Tan ◽

A.C. Dueck ◽

P. Flynn ◽

P. Steen ◽

D. Anderson ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

North Central ◽

Previously Treated

N0539 Phase II Trial of Fulvstrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor: A North Central Cancer Treatment Group Trial.

10.1158/0008-5472.sabcs-09-4096 ◽

2009 ◽

Cited By ~ 1

Author(s):

W. Tan ◽

A. Dueck ◽

P. Flynn ◽

P. Steen ◽

D. Anderson ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Group ◽

Cancer Treatment ◽

Aromatase Inhibitor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

North Central ◽

Previously Treated ◽

Group Trial

Comparison of binary efficacy endpoints in 11 North Central Cancer Treatment Group phase II metastatic breast cancer clinical trials.

10.1158/0008-5472.sabcs-6147 ◽

2009 ◽

Author(s):

AC Dueck ◽

DW Hillman ◽

H Liu ◽

KM Rowland ◽

FM Palmieri ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Treatment Group ◽

Cancer Treatment ◽

Phase Ii ◽

Metastatic Breast ◽

Cancer Clinical Trials ◽